Two views are necessary in 3D breast screening to ensure cancer is optimally visualized

NewsGuard 100/100 Score

One view 3D breast screening (tomosynthesis) means less radiation dose and about five seconds less compression, but a study from Yale University, New Haven, CT, found that obtaining both views is necessary to help ensure that a cancer won't be missed.

There are practices in Europe that have reported performing only a single view, specifically the mediolateral oblique (MLO) view, said Dr. Noa Beck, the lead author of the study. Two views are standard in the U.S. for 3D breast screening; "we wanted to see if one view would be sufficient," she said. Seven breast imagers reviewed 164 cancers visualized with tomosynthesis and noted on what views the cancers could be seen. The study found that 56% of cancers were equally well seen on both the MLO view and the craniocaudal (CC) view; 34% of the cancers were either better or only seen on the CC view, said Dr. Beck. "The CC view achieves better compression, and this likely explains the reason the CC view showed lesions more clearly. In a few cases, lesions were only seen on the MLO view because of where the cancers were located in the breast," she said.

The study results emphasize that "obtaining both views is necessary to ensure that a cancer will be optimally visualized," said Dr. Beck.

Dr. Beck will present her study at the ARRS annual meeting on April 19 in Washington, DC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions